Market Research Logo

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
    • The report reviews Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


    Introduction
    Global Markets Direct Report Coverage
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) Overview
    Therapeutics Development
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Stage of Development
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Therapy Area
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Indication
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Products Glance
    Late Stage Products
    Early Stage Products
    Unknown Stage Products
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Companies
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Products under Development by Universities/Institutes
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Therapeutics Assessment
    Assessment by Monotherapy/Combination Products
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Companies Involved in Therapeutics Development
    1st Order Pharmaceuticals Inc
    Grunenthal GmbH
    Saniona AB
    SciFluor Life Sciences, LLC
    Valeant Pharmaceuticals International, Inc.
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Drug Profiles
    1OP-2198 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ezogabine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NH-34 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-0034 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate KCNQ and TSPO for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Discontinued Products
    Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Featured News & Press Releases
    Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
    Apr 16, 2015: The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute Collaborate with GlaxoSmithKline on New ALS Clinical Trial
    Feb 04, 2015: Anti-epilepsy drug preserves brain function after stroke
    Jan 08, 2015: SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
    Jun 25, 2013: SciFluor Life Sciences Presents New Preclinical Data For SF0034 At 30th International Epilepsy Congress
    May 31, 2013: EMA's CHMP Recommends Restricting Trobalt To Last-line Therapy In Partial Epilepsy
    May 27, 2013: Valeant Pharma's Retigabine Shows Promise In Preventing Noise-induced Tinnitus In Animal Model, Pitt Researchers Report
    Jul 27, 2011: Glaxosmithkline's Drug Retigabine Added To NHS Treatment Options
    Jun 16, 2011: Retigabine May Further Help People With Epilepsy, NICE Says
    Jun 13, 2011: Valeant And GlaxoSmithKline Announce FDA Approval For Potiga
    Apr 18, 2011: GSK And Valeant Respond To FDA On Ezogabine
    Mar 29, 2011: GSK And Valeant Receive European Authorization For Trobalt
    Jan 21, 2011: GSK And Valeant Receive Positive Opinion In Europe From CHMP For Trobalt
    Dec 01, 2010: GSK And Valeant Receive FDA Complete Response Letter For Ezogabine
    Aug 30, 2010: GSK And Valeant Receive New FDA PDUFA Goal Date For Ezogabine
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Indication, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Number of Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Pipeline by 1st Order Pharmaceuticals Inc, H2 2016
    Pipeline by Grunenthal GmbH, H2 2016
    Pipeline by Saniona AB, H2 2016
    Pipeline by SciFluor Life Sciences, LLC, H2 2016
    Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
    Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for, H2 2016
    Number of Products under Development by Therapy Area, H2 2016
    Number of Products under Development by Top 10 Indication, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy/Combination Products, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report